



NEW APPOINTMENT FOR NORGINE IN BUSINESS DEVELOPMENT

15 March 2006

Norgine, the European specialty pharmaceutical company, today announced that Dr. Richard Taylor has joined Global Marketing & Business Development as Business Development Manager.

Richard joins from the University of Bristol where he was responsible for technology transfer deals. In that role he was responsible for the commercialisation strategy for bioscience inventions from the University of Bristol and Bristol Healthcare Trust. Prior to that he worked for 7 years in licensing at GlaxoSmithKline, following a period in R&D at Smith Kline Beecham.

ENDS

Notes to editor

Norgine is an independent, successful European specialty pharmaceutical company that has been established for 100 years and has a presence in all the major European markets. In 2005 Norgine's sales were €171 million, the 19th consecutive year of double-digit growth. The company employs over 900 people, of which 350 are in sales and marketing.

Norgine's current focus is pharmaceutical products that address significant unmet clinical need in areas such as gastroenterology, hepatology and pain management. The company currently markets a range of products in its key therapeutic areas e.g. Movicol® for the treatment of chronic constipation and faecal impaction, Klean-Prep® for bowel preparation prior to colonoscopy, and Oramorph® for the treatment of moderate to severe pain associated with cancer.

Norgine has an active Research and Development effort and currently has products at various stages of clinical development. Norgine has two manufacturing sites; Hengoed in the UK and Dreux, France.

Norgine's website is www.norgine.com

For further information, please contact:

Paul Pay, Vice-President, Business Development, Norgine

T: +44 (0)1895 453710

E: ppay@norgine.com

Louise Blakeborough, Chapter Five

T: +44 (0)1306 731800

E: lblakeborough@chapterfive.co.uk